Literature DB >> 17115150

Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.

Rajeev K Mehlotra1, Moses J Bockarie, Peter A Zimmerman.   

Abstract

OBJECTIVE: UDP-glucuronosyltransferases (UGTs) UGT1A9 and UGT2B7 are involved in the metabolism of antimalarial dihydroartemisinin and antiretroviral zidovudine. Our aim was to analyze the prevalence of UGT1A9 (chromosome 2) and UGT2B7 (chromosome 4) nonsynonymous single nucleotide polymorphisms (SNPs) in West African (WA), Papua New Guinean (PNG), and North American (NA) populations.
METHODS: Using a post-PCR ligation detection reaction-fluorescent microsphere assay, frequencies of UGT1A9 (8G > A, 98T > C, 766G > A) and UGT2B7 (211G > T, 802C > T, 1192G > A) SNPs were determined in WA (n = 133, 5 countries), PNG (n = 153), and NA (n = 350, 4 ethnic groups) individuals.
RESULTS: The UGT1A9 variant alleles were not common in the study populations. None of the SNPs were present in WA and PNG. Among NA, all 3 SNPs were present (1% each) in Asian-Americans, while 98T > C was present only in Caucasian-Americans (1%) and Hispanic-Americans (1%). Regarding UGT2B7 SNPs, the prevalence of 802C > T was 21% in WA, 28% in PNG, and 28-52% in NA. The SNP 211G > T was present only in Asian-Americans (9%) and Hispanic-Americans (2%), while 1192G > A was not present in any of the subjects. No significant linkage was observed at UGT1A9, UGT2B7, and between both the loci in any of the study populations.
CONCLUSIONS: Taken together, the UGT1A9-UGT2B7 polymorphism profile in WA and PNG populations is similar to African-Americans, but different from Asian-Americans. It is important to determine if these differences, along with previously reported differences in cytochrome P450 2B6 allele frequencies, are associated with altered metabolism/effectiveness of artemisinin drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17115150      PMCID: PMC2577308          DOI: 10.1007/s00228-006-0206-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  54 in total

Review 1.  Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases.

Authors:  Michael H Court
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

2.  Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus.

Authors:  Q H Gong; J W Cho; T Huang; C Potter; N Gholami; N K Basu; S Kubota; S Carvalho; M W Pennington; I S Owens; N C Popescu
Journal:  Pharmacogenetics       Date:  2001-06

3.  Pharmacokinetics of oral artesunate in children with moderately severe Plasmodium falciparum malaria.

Authors:  D B Bethell; P Teja-Isavadharm; X T Cao; T T Pham; T T Ta; T N Tran; T T Nguyen; T P Pham; D Kyle; N P Day; N J White
Journal:  Trans R Soc Trop Med Hyg       Date:  1997 Mar-Apr       Impact factor: 2.184

4.  Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz.

Authors:  A E Mutlib; H Chen; G A Nemeth; J A Markwalder; S P Seitz; L S Gan; D D Christ
Journal:  Drug Metab Dispos       Date:  1999-11       Impact factor: 3.922

5.  Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria.

Authors:  P Teja-Isavadharm; G Watt; C Eamsila; K Jongsakul; Q Li; G Keeratithakul; N Sirisopana; L Luesutthiviboon; T G Brewer; D E Kyle
Journal:  Am J Trop Med Hyg       Date:  2001-12       Impact factor: 2.345

Review 6.  Artemisinin and its derivatives: an important new class of antimalarial agents.

Authors:  G A Balint
Journal:  Pharmacol Ther       Date:  2001 May-Jun       Impact factor: 12.310

Review 7.  Artemisinin drugs: novel antimalarial agents.

Authors:  R N Price
Journal:  Expert Opin Investig Drugs       Date:  2000-08       Impact factor: 6.206

8.  Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria.

Authors:  Harin A Karunajeewa; Kenneth F Ilett; Kitiya Dufall; Adedayo Kemiki; Moses Bockarie; Michael P Alpers; P Hugh Barrett; Paolo Vicini; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria.

Authors:  Sadik Mithwani; Leon Aarons; Gilbert O Kokwaro; Oneeb Majid; Simon Muchohi; Geoffrey Edwards; Sumia Mohamed; Kevin Marsh; William Watkins
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

Review 10.  Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.

Authors:  S Nagar; R P Remmel
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

View more
  20 in total

1.  CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment.

Authors:  Rajeev K Mehlotra; Moses J Bockarie; Peter A Zimmerman
Journal:  Br J Clin Pharmacol       Date:  2007-03-28       Impact factor: 4.335

Review 2.  Human Genetic Variation and HIV/AIDS in Papua New Guinea: Time to Connect the Dots.

Authors:  Rajeev K Mehlotra
Journal:  Curr HIV/AIDS Rep       Date:  2018-12       Impact factor: 5.071

3.  Treatment with coartem (artemether-lumefantrine) in Papua New Guinea.

Authors:  Sonja Schoepflin; Enmoore Lin; Benson Kiniboro; Jeana T DaRe; Rajeev K Mehlotra; Peter A Zimmerman; Ivo Mueller; Ingrid Felger
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

4.  Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success.

Authors:  Rajeev K Mehlotra; Vinay K Cheruvu; Melinda J Blood Zikursh; Rebekah L Benish; Michael M Lederman; Robert A Salata; Barbara Gripshover; Grace A McComsey; Michelle V Lisgaris; Scott Fulton; Carlos S Subauste; Richard J Jurevic; Chantal Guillemette; Peter A Zimmerman; Benigno Rodriguez
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

5.  Species and inter-individual differences in metabolic capacity of di(2-ethylhexyl)phthalate (DEHP) between human and mouse livers.

Authors:  Yuki Ito; Michihiro Kamijima; Chie Hasegawa; Masahiro Tagawa; Toshio Kawai; Mio Miyake; Yumi Hayashi; Hisao Naito; Tamie Nakajima
Journal:  Environ Health Prev Med       Date:  2013-09-28       Impact factor: 3.674

6.  Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.

Authors:  Jing Li; Vincent Menard; Rebekah L Benish; Richard J Jurevic; Chantal Guillemette; Mark Stoneking; Peter A Zimmerman; Rajeev K Mehlotra
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

7.  The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants.

Authors:  Zi-Zhao Yang; Li Li; Lu Wang; Ling-Min Yuan; Ming-Cheng Xu; Jing-Kai Gu; Hui-di Jiang; Lu-Shan Yu; Su Zeng
Journal:  Acta Pharmacol Sin       Date:  2017-05-29       Impact factor: 6.150

Review 8.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

9.  Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.

Authors:  Federico Innocenti; Wanqing Liu; Donna Fackenthal; Jacqueline Ramírez; Peixian Chen; Xin Ye; Xiaolin Wu; Wei Zhang; Snezana Mirkov; Soma Das; Edwin Cook; Mark J Ratain
Journal:  Pharmacogenet Genomics       Date:  2008-08       Impact factor: 2.089

10.  Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations.

Authors:  Rebekah L Benish; Benigno Rodriguez; Peter A Zimmerman; Rajeev K Mehlotra
Journal:  Infect Genet Evol       Date:  2009-10-09       Impact factor: 3.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.